Back

Effects of evolocumab on LDL-C by race and ethnicity: an analysis of double-blind and open-label extension studies

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Lipids Drug therapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Carlos J Rodriguez

Albert Einstein Medical Center, The Bronx (United States of America)

14 More presentations in this session

Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease
Doctor C. Caselli (Pisa, IT)
Abstract Slides
Presentation thumbnail
Dalcetrapib reduces incident diabetes in patients with recent acute coronary syndrome
Professor G. Schwartz (Aurora, US)
Abstract
Presentation thumbnail
Therapeutic effect of nanoliposomal anti-PCSK9 vaccine on hypercholesterolemia and atherosclerosis in C57BL/6 mice.
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Nanoliposomal anti-PCSK9 vaccine induces long-term and safe protection against atherosclerosis in C57BL/6 mouse.
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Lipoprotein (a) and cardiovascular risk: are women at increased risk?
Doctor M. Santos (Funchal, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 7 - Lipids

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources